Introduction: Anti-CD20 therapy is an effective steroid-sparing option for pediatric idiopathic nephrotic syndrome (INS), but long-term data on immune reconstitution are limited. Methods: Thirteen pediatric INS patients (7 males) were longitudinally evaluated at baseline, first long-term follow-up (mean 5.4 years), and extended follow-up (mean 6.6 years after the first follow-up, >3 years from the last anti-CD20 infusion). Clinical outcomes, B-cell subsets, serum immunoglobulin levels, vaccine competence, and infection rates were analyzed. Results: At the first follow-up, most patients had received one (n=6) or two (n=6) anti-CD20 courses; at the extended follow-up, five had undergone additional treatments. Four patients remained relapse-free during follow-up, whereas eight of nine who had previously relapsed continued to experience disease recurrence despite further anti-CD20 therapy. Oral immunosuppressant tapering improved: three patients were off therapy at first follow-up and six at the latest. Total, transitional and mature-na & iuml;ve B cells reconstituted to normal ranges according to age over time. In contrast, total, IgM, and switched memory B cells remained significantly reduced (p<0.01). Patients in sustained remission exhibited lower switched memory B-cell counts than relapsing patients (p<0.05). Serum IgG levels increased at the extended follow-up, although six patients remained below normal. Four developed severe de novo hypogammaglobulinemia requiring long-term immunoglobulin replacement and showing increased infection susceptibility. Vaccine-specific IgG titers against tetanus and HBV remained below the limit of seroprotection despite re-immunization in most patients. Conclusions: Anti-CD20 therapy offers durable disease control and allows immunosuppressant reduction in pediatric INS, but persistent memory B-cell and humoral impairment warrant long-term immunologic monitoring.

Colucci, M., Riganati, M., Zotta, F., Gargiulo, A., Massella, L., Ruggiero, B., et al. (2025). Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1736921].

Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up

Riganati M.;Cotugno N.;
2025-12-18

Abstract

Introduction: Anti-CD20 therapy is an effective steroid-sparing option for pediatric idiopathic nephrotic syndrome (INS), but long-term data on immune reconstitution are limited. Methods: Thirteen pediatric INS patients (7 males) were longitudinally evaluated at baseline, first long-term follow-up (mean 5.4 years), and extended follow-up (mean 6.6 years after the first follow-up, >3 years from the last anti-CD20 infusion). Clinical outcomes, B-cell subsets, serum immunoglobulin levels, vaccine competence, and infection rates were analyzed. Results: At the first follow-up, most patients had received one (n=6) or two (n=6) anti-CD20 courses; at the extended follow-up, five had undergone additional treatments. Four patients remained relapse-free during follow-up, whereas eight of nine who had previously relapsed continued to experience disease recurrence despite further anti-CD20 therapy. Oral immunosuppressant tapering improved: three patients were off therapy at first follow-up and six at the latest. Total, transitional and mature-na & iuml;ve B cells reconstituted to normal ranges according to age over time. In contrast, total, IgM, and switched memory B cells remained significantly reduced (p<0.01). Patients in sustained remission exhibited lower switched memory B-cell counts than relapsing patients (p<0.05). Serum IgG levels increased at the extended follow-up, although six patients remained below normal. Four developed severe de novo hypogammaglobulinemia requiring long-term immunoglobulin replacement and showing increased infection susceptibility. Vaccine-specific IgG titers against tetanus and HBV remained below the limit of seroprotection despite re-immunization in most patients. Conclusions: Anti-CD20 therapy offers durable disease control and allows immunosuppressant reduction in pediatric INS, but persistent memory B-cell and humoral impairment warrant long-term immunologic monitoring.
18-dic-2025
Pubblicato
Rilevanza internazionale
Articolo
Esperti non anonimi
Settore MEDS-08/B - Nefrologia
English
B cells; anti-CD20 treatment; hypogammaglobulinaemia, idiopathic nephrotic syndrome (INS);
immunological memory; pediatric nephrology
Colucci, M., Riganati, M., Zotta, F., Gargiulo, A., Massella, L., Ruggiero, B., et al. (2025). Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1736921].
Colucci, M; Riganati, M; Zotta, F; Gargiulo, A; Massella, L; Ruggiero, B; Cotugno, N; Ricci, G; Palma, P; Emma, F; Vivarelli, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
fimmu-16-1736921.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/448465
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact